Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
Histological status of axillary lymph nodes is an important prognostic factor in patients receiving surgery for breast cancer (BC). Sentinel lymph node (SLN) biopsy (B) has rapidly replaced axillary lymph node dissection (ALND), and is now the standard of care for axillary staging in patients with c...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2016
|
| _version_ | 1826273130075652096 |
|---|---|
| author | Andreis, D Bonardi, S Allevi, G Aguggini, S Gussago, F Milani, M Strina, C Spada, D Ferrero, G Ungari, M Rocca, A Nanni, O Roviello, G Berruti, A Harris, A Fox, S Roviello, F Polom, K Bottini, A Generali, D |
| author_facet | Andreis, D Bonardi, S Allevi, G Aguggini, S Gussago, F Milani, M Strina, C Spada, D Ferrero, G Ungari, M Rocca, A Nanni, O Roviello, G Berruti, A Harris, A Fox, S Roviello, F Polom, K Bottini, A Generali, D |
| author_sort | Andreis, D |
| collection | OXFORD |
| description | Histological status of axillary lymph nodes is an important prognostic factor in patients receiving surgery for breast cancer (BC). Sentinel lymph node (SLN) biopsy (B) has rapidly replaced axillary lymph node dissection (ALND), and is now the standard of care for axillary staging in patients with clinically node-negative (N0) operable BC. The aim of this study is to compare pretreatment lymphoscintigraphy with a post primary systemic treatment (PST) scan in order to reduce the false-negative rates for SLNB.In this single-institution study we considered 170 consecutive T2-4 N0-1 M0 BC patients treated with anthracycline-based PST. At the time of incisional biopsy, we performed sentinel lymphatic mapping. After PST, all patients repeated lymphoscintigraphy with the same methodology. During definitive surgery we performed further sentinel lymphatic mapping, SLNB and ALND.The SLN was removed in 158/170 patients giving an identification rate of 92.9% (95% confidence interval (CI) = 88.0-96.3%) and a false-negative rate of 14.0% (95% CI = 6.3-25.8%). SLNB revealed a sensitivity of 86.0% (95% CI = 74.2-93.7%), an accuracy of 94.9% (95% CI = 90.3-97.8%) and a negative predictive value of 92.7% (95% CI = 86.1-96.8%).Identification rate, sensitivity and accuracy are in accordance with other studies on SLNB after PST, even after clinically negative node conversion following PST. This study confirms that diagnostic biopsy and neoadjuvant chemotherapy maintain breast lymphatic drainage unaltered. |
| first_indexed | 2024-03-06T22:23:29Z |
| format | Journal article |
| id | oxford-uuid:55d9af3b-de89-4f70-a401-a3b588cf37fa |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:23:29Z |
| publishDate | 2016 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:55d9af3b-de89-4f70-a401-a3b588cf37fa2022-03-26T16:46:52ZSentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:55d9af3b-de89-4f70-a401-a3b588cf37faEnglishSymplectic Elements at OxfordElsevier2016Andreis, DBonardi, SAllevi, GAguggini, SGussago, FMilani, MStrina, CSpada, DFerrero, GUngari, MRocca, ANanni, ORoviello, GBerruti, AHarris, AFox, SRoviello, FPolom, KBottini, AGenerali, DHistological status of axillary lymph nodes is an important prognostic factor in patients receiving surgery for breast cancer (BC). Sentinel lymph node (SLN) biopsy (B) has rapidly replaced axillary lymph node dissection (ALND), and is now the standard of care for axillary staging in patients with clinically node-negative (N0) operable BC. The aim of this study is to compare pretreatment lymphoscintigraphy with a post primary systemic treatment (PST) scan in order to reduce the false-negative rates for SLNB.In this single-institution study we considered 170 consecutive T2-4 N0-1 M0 BC patients treated with anthracycline-based PST. At the time of incisional biopsy, we performed sentinel lymphatic mapping. After PST, all patients repeated lymphoscintigraphy with the same methodology. During definitive surgery we performed further sentinel lymphatic mapping, SLNB and ALND.The SLN was removed in 158/170 patients giving an identification rate of 92.9% (95% confidence interval (CI) = 88.0-96.3%) and a false-negative rate of 14.0% (95% CI = 6.3-25.8%). SLNB revealed a sensitivity of 86.0% (95% CI = 74.2-93.7%), an accuracy of 94.9% (95% CI = 90.3-97.8%) and a negative predictive value of 92.7% (95% CI = 86.1-96.8%).Identification rate, sensitivity and accuracy are in accordance with other studies on SLNB after PST, even after clinically negative node conversion following PST. This study confirms that diagnostic biopsy and neoadjuvant chemotherapy maintain breast lymphatic drainage unaltered. |
| spellingShingle | Andreis, D Bonardi, S Allevi, G Aguggini, S Gussago, F Milani, M Strina, C Spada, D Ferrero, G Ungari, M Rocca, A Nanni, O Roviello, G Berruti, A Harris, A Fox, S Roviello, F Polom, K Bottini, A Generali, D Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer |
| title | Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer |
| title_full | Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer |
| title_fullStr | Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer |
| title_full_unstemmed | Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer |
| title_short | Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer |
| title_sort | sentinel lymph node surgery after neoadjuvant chemotherapy in patients with t2 to t4 n0 and n1 breast cancer |
| work_keys_str_mv | AT andreisd sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT bonardis sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT allevig sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT agugginis sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT gussagof sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT milanim sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT strinac sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT spadad sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT ferrerog sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT ungarim sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT roccaa sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT nannio sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT roviellog sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT berrutia sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT harrisa sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT foxs sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT roviellof sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT polomk sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT bottinia sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer AT generalid sentinellymphnodesurgeryafterneoadjuvantchemotherapyinpatientswitht2tot4n0andn1breastcancer |